MTOR and renal cell carcinoma: Although different therapeutic agents, including, multiple kinase inhibitors (like, sorafenib, sunitinib, cabozantinib and others), mammalian target of Rapamycin (mTOR )inhibitors, and some immune checkpoint inhibitors have been suggested as first-line treatment for advanced RCC, the treatment responses are not long-standing; and the tumors progress due to drug resistance and immune escape [2,3,4].